Walgreens Boots Alliance, Inc. (NASDAQ:WBA) Holdings Decreased by KLCM Advisors Inc.

KLCM Advisors Inc. lessened its stake in shares of Walgreens Boots Alliance, Inc. (NASDAQ:WBA - Free Report) by 12.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 670,688 shares of the pharmacy operator's stock after selling 98,432 shares during the quarter. Walgreens Boots Alliance comprises about 2.7% of KLCM Advisors Inc.'s holdings, making the stock its 13th biggest holding. KLCM Advisors Inc. owned 0.08% of Walgreens Boots Alliance worth $17,512,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. EverSource Wealth Advisors LLC lifted its position in shares of Walgreens Boots Alliance by 308.4% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,119 shares of the pharmacy operator's stock worth $25,000 after buying an additional 845 shares during the last quarter. Highlander Capital Management LLC purchased a new stake in Walgreens Boots Alliance in the 4th quarter valued at $26,000. Venturi Wealth Management LLC raised its position in Walgreens Boots Alliance by 1,241.8% in the 4th quarter. Venturi Wealth Management LLC now owns 1,060 shares of the pharmacy operator's stock valued at $28,000 after purchasing an additional 981 shares during the last quarter. FinTrust Capital Advisors LLC raised its position in Walgreens Boots Alliance by 2,314.5% in the 3rd quarter. FinTrust Capital Advisors LLC now owns 1,328 shares of the pharmacy operator's stock valued at $30,000 after purchasing an additional 1,273 shares during the last quarter. Finally, Rocky Mountain Advisers LLC purchased a new stake in Walgreens Boots Alliance in the 4th quarter valued at $30,000. Hedge funds and other institutional investors own 58.59% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Bank of America reduced their price target on shares of Walgreens Boots Alliance from $23.00 to $22.00 and set an "underperform" rating for the company in a research report on Tuesday, March 26th. TD Cowen reduced their price target on shares of Walgreens Boots Alliance from $37.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, April 3rd. Morgan Stanley reduced their price target on shares of Walgreens Boots Alliance from $21.00 to $20.00 and set an "underweight" rating for the company in a research report on Monday, April 1st. Leerink Partnrs reissued a "market perform" rating on shares of Walgreens Boots Alliance in a research note on Monday, February 26th. Finally, Truist Financial reissued a "hold" rating and issued a $25.00 price objective on shares of Walgreens Boots Alliance in a research note on Monday, April 1st. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Walgreens Boots Alliance currently has a consensus rating of "Hold" and an average price target of $24.36.

Insider Buying and Selling at Walgreens Boots Alliance

In other news, Director Valerie B. Jarrett bought 4,456 shares of Walgreens Boots Alliance stock in a transaction on Monday, January 29th. The shares were bought at an average cost of $22.44 per share, for a total transaction of $99,992.64. Following the acquisition, the director now owns 4,456 shares in the company, valued at $99,992.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Inderpal S. Bhandari acquired 3,000 shares of the business's stock in a transaction dated Thursday, April 11th. The shares were acquired at an average cost of $18.05 per share, for a total transaction of $54,150.00. Following the acquisition, the director now directly owns 3,000 shares in the company, valued at approximately $54,150. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Valerie B. Jarrett acquired 4,456 shares of the business's stock in a transaction dated Monday, January 29th. The shares were bought at an average price of $22.44 per share, for a total transaction of $99,992.64. Following the completion of the acquisition, the director now owns 4,456 shares in the company, valued at $99,992.64. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 13,456 shares of company stock worth $270,423. Corporate insiders own 17.40% of the company's stock.

Walgreens Boots Alliance Price Performance

Shares of NASDAQ:WBA traded down $0.01 on Wednesday, reaching $17.63. 7,695,416 shares of the company were exchanged, compared to its average volume of 14,350,901. The firm has a market cap of $15.21 billion, a price-to-earnings ratio of -2.52, a price-to-earnings-growth ratio of 1.09 and a beta of 0.73. Walgreens Boots Alliance, Inc. has a 1-year low of $17.53 and a 1-year high of $36.14. The company has a 50-day moving average of $20.60 and a 200-day moving average of $21.98. The company has a current ratio of 0.66, a quick ratio of 0.32 and a debt-to-equity ratio of 0.50.

Walgreens Boots Alliance (NASDAQ:WBA - Get Free Report) last issued its quarterly earnings data on Thursday, March 28th. The pharmacy operator reported $1.20 EPS for the quarter, beating analysts' consensus estimates of $0.82 by $0.38. The firm had revenue of $37.05 billion for the quarter, compared to analysts' expectations of $35.86 billion. Walgreens Boots Alliance had a negative net margin of 4.18% and a positive return on equity of 12.11%. The firm's revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.16 EPS. Equities analysts forecast that Walgreens Boots Alliance, Inc. will post 3.23 earnings per share for the current fiscal year.

Walgreens Boots Alliance Profile

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.